1. Search Result
Search Result
Isoforms Recommended: CDK1
Results for "

Cdk-1

" in MedChemExpress (MCE) Product Catalog:

112

Inhibitors & Agonists

2

Peptides

6

Natural
Products

8

Recombinant Proteins

3

Isotope-Labeled Compounds

5

Antibodies

2

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-RS02348

    Small Interfering RNA (siRNA) Others

    CDK1 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CDK1 Human Pre-designed siRNA Set A
    CDK1 Human Pre-designed siRNA Set A
  • HY-RS02349

    Small Interfering RNA (siRNA) Others

    Cdk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdk1 Mouse Pre-designed siRNA Set A
    Cdk1 Mouse Pre-designed siRNA Set A
  • HY-RS02350

    Small Interfering RNA (siRNA) Others

    Cdk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdk1 Rat Pre-designed siRNA Set A
    Cdk1 Rat Pre-designed siRNA Set A
  • HY-115924

    CDK Cancer
    CDK1-IN-1 is a potent CDK1 inhibitor (CDK1/CycB IC50=161.2 nM) with potential antiproliferative activity and selectivity for cancer tissues. CDK1-IN-1 induces apoptosis in p53 dependent manner through the intrinsic apoptotic pathway. CDK1-IN-1 is a potential targeted antitumor agent [1].
    <em>CDK1</em>-IN-<em>1</em>
  • HY-151409

    CDK Cancer
    CDK1-IN-5 (10h) is a selective CDK1 inhibitor with IC50s of 42.19, 188.71 and 354.15 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-5 inhibits growth of cancer cells by affecting cell cycle. CDK1-IN-5 can be used for the research of cancer [1].
    <em>CDK1</em>-IN-5
  • HY-151407

    CDK Cancer
    CDK1-IN-3 (8g) is a selective CDK1 inhibitor with IC50s of 36.8, 305.17 and 369.37 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-3 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-3 can be used for the research of cancer [1].
    <em>CDK1</em>-IN-3
  • HY-151408

    CDK Cancer
    CDK1-IN-4 (10d) is a selective CDK1 inhibitor with IC50s of 44.52, 624.93 and 135.22 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN4 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-4 can be used for the research of cancer [1].
    <em>CDK1</em>-IN-4
  • HY-112463

    CDK Cancer
    CDK1-IN-2 is a CDK1 inhibitor (IC50: 5.8 μM) [1].
    <em>CDK1</em>-IN-2
  • HY-112462

    CDK Cancer
    Cdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor, with an IC50 of 2.1 μM for CDK1/cyclin B [1].
    <em>Cdk1</em>/2 Inhibitor III
  • HY-147646

    CDK Apoptosis Cancer
    CDK1/Cyc B-IN-1 (Compound 5) is a selective CDK1/Cyc B complex inhibitor with an IC50 of 97 nM. CDK1/Cyc B-IN-1 triggers apoptosis and G2/M cell cycle arrest. CDK1/Cyc B-IN-1 shows broad-spectrum cytotoxic action against cancer cell lines [1].
    <em>CDK1</em>/Cyc B-IN-<em>1</em>
  • HY-146253

    CDK Apoptosis Bcl-2 Family Caspase Cancer
    CDK1/2/4-IN-1 (compound 3a) is a potent CDK inhibitor with IC50 values of 1.47, 0.78 and 0.87 μM for CDK1, CDK2 and CDK4, respectively. CDK1/2/4-IN-1 arrests cell cycle at G2/M phase and induces apoptosis. CDK1/2/4-IN-1 elevates Bax, caspase-3, P53 levels and decreases Bcl-2 level. CDK1/2/4-IN-1 can be used for cancer research [1].
    <em>CDK1</em>/2/4-IN-<em>1</em>
  • HY-147901

    Histone Demethylase CDK Apoptosis Caspase Cancer
    KDM1/CDK1-IN-1 (compound 4) is a potent KDM1 and CDK1 inhibitor, with IC50 values of 0.096 and 0.078 μM, respectively.KDM1/CDK1-IN-1 induces cell cycle arrest at G2/M phase and apoptosis in HOP-92 cells. KDM1/CDK1-IN-1 exhibits potent cytotoxic activity against the CCRF-CEM, HOP-92 and Hep-G2 cells, with IC50 values of 16.34, 3.45 and 7.79 μM, respectively [1].
    KDM<em>1</em>/<em>CDK1</em>-IN-<em>1</em>
  • HY-12529
    Ro-3306
    30+ Cited Publications

    CDK Apoptosis Cancer
    Ro-3306 is a potent and selective inhibitor of CDK1, with Kis of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.
    Ro-3306
  • HY-144637

    Apoptosis Autophagy Cancer
    Autophagy inducer 2 (Compound 11i) is a potent autophagy inducer. Autophagy inducer 2 exhibits apparent antiproliferative activity against the MCF-7 cell line with an IC50 value of 1.31 μM and remarkably inhibits the colony formation of the MCF-7 cells. Autophagy inducer 2 arrests the MCF-7 cells in the G2/M phase by regulating the cell-cycle-related proteins Cdk-1 and Cyclin B1. Autophagy inducer 2 has the potential for the research of breast cancer [1].
    Autophagy inducer 2
  • HY-137432B
    Avotaciclib hydrochloride
    1 Publications Verification

    BEY1107 hydrochloride

    CDK Cancer
    Avotaciclib hydrochloride is the hydrochloride form of Avotaciclib (HY-137432), a CDK1 inhibitor. Avotaciclib hydrochloride can be used for a few specific cancers, such as pancreatic cancer, in which CDK1 is abnormal and strongly expressed [1].
    Avotaciclib hydrochloride
  • HY-15569

    CDK Cancer
    NU6102 is a potent CDK1 and CDK2 inhibitor with IC50s of 9.5 nM and 5.4 nM for CDK1/cyclinB and CDK2/cyclinA3, respectively. NU6102 shows selectivity for CDK1/CDK2 over CDK4 (IC50 of 1.6 μM), DYRK1A (IC50 of 0.9 μM), PDK1 (IC50 of 0.8 μM) and ROCKII (IC50 of 0.6 μM) [1] .
    NU6102
  • HY-10329
    JNJ-7706621
    2 Publications Verification

    Aurora Kinase CDK Apoptosis Cancer
    JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC50s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, aurora-A and aurora-B, respectively [1] .
    JNJ-7706621
  • HY-10580
    GSK 3 Inhibitor IX
    5+ Cited Publications

    6-Bromoindirubin-3'-oxime; BIO; MLS 2052

    GSK-3 CDK Apoptosis Cancer
    GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex with IC50s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.
    GSK 3 Inhibitor IX
  • HY-103647

    CDK VEGFR GSK-3 Cancer
    K00546 is a potent CDK1 and CDK2 inhibitor with IC50s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. K00546 is also a potent CDC2-like kinase 1 (CLK1) and CLK3 inhibitor with IC50s of 8.9 nM and 29.2 nM, respectively [1] .
    K00546
  • HY-103381

    CDK GSK-3 Cancer
    NSC693868 is a selective inhibitor of CDK1 and CDK5 with IC50s of 600 nM and 400 nM, respectively. NSC693868 less potently inhibits GSK3β with an IC50 of 1 µM) and does not block CDC25 activity. NSC693868 is used to help define the roles of CDK1 and CDK5 in various signaling pathways [1].
    NSC693868
  • HY-114779

    CDK Cancer
    N9-Isopropylolomoucine is a mitotic cyclin dependent kinase (CDK) inhibitor. N9-Isopropylolomoucine targets CCNB 1/CDK1 and can be used for cancer research [1].
    N9-Isopropylolomoucine
  • HY-103221

    Aryl Hydrocarbon Receptor GSK-3 CDK Others
    MeBIO is a potent AhR (aryl hydrocarbon receptor) agonist, with IC50 of 44 μM (GSK-3) and 55 μM (CDK1/cyclin B), respectively. MeBIO is inactive on GSK-3β [1].
    MeBIO
  • HY-10005
    Flavopiridol
    30+ Cited Publications

    HMR-1275; Alvocidib; L86-8275

    CDK Autophagy HIV Apoptosis Cancer
    Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.
    Flavopiridol
  • HY-18629
    SU9516
    4 Publications Verification

    CDK Autophagy Apoptosis Cancer
    SU9516 is a potent CDK2 inhibitor, with an IC50 of 22 nM, and also shows inhibitory effects on CDK1 and CDK4, with IC50s of 40, 200 nM, respectively.
    SU9516
  • HY-10006
    Flavopiridol Hydrochloride
    30+ Cited Publications

    Alvocidib Hydrochloride; L86-8275 Hydrochloride; HMR-1275 Hydrochloride

    CDK Autophagy HIV Cancer
    Flavopiridol Hydrochloride (Alvocidib Hydrochloride) is a broad inhibitor of CDK, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.
    Flavopiridol Hydrochloride
  • HY-10492
    Dinaciclib
    35+ Cited Publications

    SCH 727965

    CDK Apoptosis Cancer
    Dinaciclib (SCH 727965) is a potent inhibitor of CDK, with IC50s of 1 nM, 1 nM, 3 nM, and 4 nM for CDK2, CDK5, CDK1, and CDK9, respectively [1].
    Dinaciclib
  • HY-15241

    LCQ-195; AT9311

    CDK Cancer
    NVP-LCQ195 (AT9311; LCQ195) is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.
    NVP-LCQ195
  • HY-137432

    BEY1107

    CDK Cancer
    Avotaciclib (BEY1107) is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib can be used for the research of locally advanced or metastatic pancreatic cancer [1].
    Avotaciclib
  • HY-137432A
    Avotaciclib trihydrochloride
    1 Publications Verification

    BEY1107 trihydrochloride

    CDK Cancer
    Avotaciclib (BEY1107) trihydrochloride is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib trihydrochloride can be used for the research of locally advanced or metastatic pancreatic cancer [1].
    Avotaciclib trihydrochloride
  • HY-117535
    CDK2-IN-4
    2 Publications Verification

    CDK Cancer
    CDK2-IN-4 (compound 73) is a potent and selective CDK2 inhibitor with an IC50 of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM) [1].
    <em>CDK</em>2-IN-4
  • HY-112336

    CDK GSK-3 Neurological Disease
    Aloisine RP106 (compound 38) is a potent inhibitor of Cdk1/cyclin B, Cdk5/p25, and GSK3 with IC50s of 0.70µM, 1.5µM, 0.92 µM, respectively [1].
    Aloisine RP106
  • HY-13266A
    BS-181 hydrochloride
    4 Publications Verification

    CDK Cancer
    BS-181 hydrochloride is a highly selective CDK7 inhibitor with IC50 of 21 nM, and > 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.
    BS-181 hydrochloride
  • HY-10014
    R547
    2 Publications Verification

    CDK GSK-3 Apoptosis Cancer
    R547 is a potent, selective and orally active ATP-competitive CDK inhibitor, with Kis of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively [1] .
    R547
  • HY-50943
    AT7519 Hydrochloride
    10+ Cited Publications

    CDK Apoptosis Cancer
    AT7519 Hydrochloride is a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.
    AT7519 Hydrochloride
  • HY-13914

    BAY 1000394

    CDK Cancer
    Roniciclib is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC50s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.
    Roniciclib
  • HY-111930

    GSK-3 CDK Cancer
    5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase, with IC50s of 9, 20 and 25 nM, respectively [1].
    5-Iodo-indirubin-3'-monoxime
  • HY-50940
    AT7519
    10+ Cited Publications

    AT7519M

    CDK Apoptosis Cancer
    AT7519 (AT7519M) as a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.
    AT7519
  • HY-N12625A

    CDK Cancer
    (S)-(-)-O-Demethylbuchenavianine (Compound (S)-(−)-1) is a flavonoidal alkaloids. (S)-(-)-O-Demethylbuchenavianine is a potent CDK inhibitor, with IC50 values of 0.03 and 0.05 μM for CDK1 and CDK5, respectively [1].
    (S)-(-)-O-Demethylbuchenavianine
  • HY-50940A
    AT7519 TFA
    10+ Cited Publications

    AT7519M TFA

    CDK Cancer
    AT7519 (AT7519M) TFA as a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.
    AT7519 TFA
  • HY-15777A
    Ribociclib hydrochloride
    Maximum Cited Publications
    51 Publications Verification

    LEE011 hydrochloride

    CDK Cancer
    Ribociclib hydrochloride (LEE011 hydrochloride) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.
    Ribociclib hydrochloride
  • HY-111931

    CDK GSK-3 Cancer
    Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of CDK1, CDK5, and GSK-3β with IC50s of 5 nM, 7 nM, and 80 nM, respectively [1].
    Indirubin-3'-monoxime-5-sulphonic acid
  • HY-111237

    Olomoucin

    CDK Cancer
    Butyrolactone I is an ATP-competitive inhibitor of CDK1 as a secondary metabolite from A. terreus [1]. Butyrolactone I has antitumor effects in non-small cell lung, small cell lung, and prostate cancer cell lines .
    Butyrolactone I
  • HY-153556

    CDK VEGFR Src Others
    GW297361 is an oxindole CDK inhibitor that elicits a Pho85-selective response in cells. GW297361 inhibits yeast Cdk1 and Pho85 with IC50s of 20 nM and 400 nM in vitro, respectively [1].
    GW297361
  • HY-103383

    CDK Casein Kinase Neurological Disease Cancer
    (R)-DRF053 dihydrochloride is a potent casein kinases 1 (CK1), CDK1/cyclin B and CDK5/p25 inhibitor with IC50s of 14 nM, 220 nM and 80 nM, respectively. (R)-DRF053 dihydrochloride prevents the CK1-dependent production of amyloid-beta in a cell model [1].
    (R)-DRF053 dihydrochloride
  • HY-15777
    Ribociclib
    Maximum Cited Publications
    51 Publications Verification

    LEE011

    CDK Cancer
    Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex [1].
    Ribociclib
  • HY-144117

    CDK Metabolic Disease
    GFB-12811 is a high selective and orally active CDK5 inhibitor with an IC50 of 2.3 nM. GFB-12811 is highly selective over the other tested kinases (CDK1/2/6/7/9) [1].
    GFB-12811
  • HY-N11774

    Apoptosis Caspase Cancer
    Euphornin is a anticaner agent, that can be isolated from E. helioscopia. Euphornin induces apoptosis via caspase-mediated pathways. Euphornin induces cell cycle arrest by increasing the level of the phospho-CDK1 (Tyr15) protein [1].
    Euphornin
  • HY-15777B
    Ribociclib succinate
    Maximum Cited Publications
    51 Publications Verification

    LEE011 succinate

    CDK Cancer
    Ribociclib succinate (LEE011 succinate) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.
    Ribociclib succinate
  • HY-15777C
    Ribociclib succinate hydrate
    Maximum Cited Publications
    51 Publications Verification

    LEE011 succinate hydrate

    CDK Cancer
    Ribociclib succinate hydrate (LEE011 succinate hydrate) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.
    Ribociclib succinate hydrate
  • HY-16559A

    P276-00 free base

    CDK Cancer
    Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively [1] . Riviciclib shows antitumor activity on cisplatin-resistant cells .
    Riviciclib

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: